Regulatory
Sep 20, 2026 · 1 min read · 44,401 views
FDA extends review of Exelixis' colorectal cancer drug candidate
S
Sophia Reyes
Editorial · Sep 20, 2026
California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data led
← Previous
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal
Next →
Three deaths in China shake trust in the country's speedy clinical trial system
